7-7- 2010 NEWS
Medizone Files for International Patent Protection
SAN FRANCISCO, July 7 /PRNewswire-FirstCall/ -- Medizone International, Inc. (OTC Bulletin Board: MZEI) has filed an international patent application under the auspices of the Patent Co-operation Treaty (PCT) to secure international patent protection for its Asepticsure™ technology. The international patent application consolidates the two previously filed patent applications titled "Healthcare Facility Disinfecting System" and "Disinfecting Process and Apparatus." It brings up-to-date and expands the technical evidence, both laboratory scale and practical scale, supporting the effectiveness of the technology in clearing healthcare and other critical infrastructure of bacterial infections such as C. difficile, MRSA, E coli, Pseudomonas aeruginous and VRE down to complete sterilization standard.
After the international patent application has been searched and examined by the International Patent Office authorities, Medizone can register it in any or all countries of the world that have ratified the PCT (of which there are over 140 such countries, which includes all major industrialized countries), and secure grant of patents on the application in countries of its choice.
Medizone International, Inc., is a research and development company engaged in developing its AsepticSure™ System to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. A government variant is being developed for bio-terrorism counter measures. Research is conducted at Medizone's dedicated laboratories located in Innovation Park, Queen's University in Kingston, Ontario, Canada.
This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.